Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same

Patent metadata

Field	Value
Publication number	US-11814679-B2
Application number	US-201716061591-A
Country	US
Kind code	B2
Filing date	Jan 10, 2017
Priority date	Jan 11, 2016
Publication date	Nov 14, 2023
Grant date	Nov 14, 2023

Abstract

The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.

First claim

That which is claimed is:

1. A method of treating a subject having a cancer that expresses a tumor antigen, which cancer is amenable to CD8+ T cell therapy and IL-10 therapy, the method comprising the following steps:
(a) isolating CD8+ T cells from the subject and generating a reference T cell receptor (TCR) sample comprising a nucleic acid sequence encoding Vα TCR polypeptides and a nucleic acid sequence Vβ T cell receptor polypeptides from the isolated CD8+ T cells;
(b) administering to the subject an IL-10 agent and subsequently isolating CD8+ T cells from the subject;
(c) generating a test TCR sample comprising a nucleic acid sequence encoding the Vα TCR polypeptide and the nucleic acid sequence encoding a Vβ TCR polypeptide from the isolated CD8+ T cells of step (b);
(d) administering to the subject a CD8+ T cell, wherein the T cell is genetically modified to express a recombinant TCR, the modified T cell comprising a sequence encoding the nucleic acid sequence encoding the Vα TCR polypeptide and the nucleic acid sequence encoding the Vβ TCR polypeptide of step (a) or (c)
wherein, the sequence encoding the Vα TCR polypeptide and the sequences encoding the Vβ TCR polypeptide are increased in abundance in the test TCR sample as compared to the reference TCR sample; and
wherein said administering is effective to treat the cancer in the subject.

2. The method of claim 1 , wherein the Vα TCR polypeptide and the Vβ TCR polypeptide of the genetically modified T cell are encoded from separate expression cassettes of the same or different expression constructs.

3. The method of claim 1 , wherein the Vα TCR polypeptide of the genetically modified T cell is encoded by the construct is operably linked at its C-terminus to a constant alpha TCR polypeptide.

4. The method of claim 1 , wherein the Vβ TCR polypeptide of the genetically modified T cell is encoded by the construct is operably linked at is C-terminus to a beta constant TCR polypeptide.

5. The method of claim 1 , wherein the Vβ TCR polypeptide and the Vα TCR polypeptide of the CD8+ T cell are encoded by a construct comprising a nucleic acid encoding a single chain TCR (scTv) comprising the Vβ TCR polypeptide and the Vα TCR polypeptide.

6. The method of claim 5 , wherein the scTv comprises, from N-terminus to C-terminus, the Vβ TCR polypeptide, a linker, and the Vα TCR polypeptide.

7. The method of claim 1 , wherein the cancer is a solid tumor.

8. The method of claim 7 , wherein the tumor is a tumor of a cancer selected from cancer of the uterus, cervix, breast, prostate, testes, gastrointestinal tract, kidney, renal cell, bladder, bone, bone marrow, skin, head or neck, liver, gall bladder, heart, lung, pancreas, salivary gland, adrenal gland, thyroid, brain, ganglia, central nervous system (CNS) and peripheral nervous system (PNS), or cancer of the hematopoietic system, spleen, or thymus.

9. The method of claim 7 , wherein the cancer is a cancer of the esophagus, oropharynx, stomach, small intestine, large intestine, colon, or rectum.

10. The method of claim 7 , wherein the cancer is melanoma, colorectal cancer, or renal cancer.

11. The method of claim 1 , wherein the method further comprises: step (c) administering to the subject an IL-10 agent after the subject is administered the genetically modified T cell of step (b).

12. The method of claim 1 , wherein the Vα TCR polypeptide and the Vβ TCR polypeptide are increased in abundance by at least 10-fold in the test TCR sample as compared to the reference TCR sample.

13. The method of claim 1 , wherein the subject is responsive to the IL-10 agent.

Assignees

• Lilly Co Eli

Inventors

• Mumm John Brian
• Chan Ivan Ho
• Mccauley Scott
• Ogg Scott
• Oft Martin

Classifications

• A61K40/4201

  Neoantigens · CPC title

• A61K40/421

  Immunoglobulin superfamily · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title